NCT05825404Completed
Smart Lighting for Nursing Home Residents With Dementia
The Effect of Smart Ambient Bright Light for Nursing Home Residents With Alzheimer's Disease and Related Dementias
Source: ClinicalTrials.gov · Last updated 8 Aug 2025
Brief summary (registry, in English)
This proposed study seeks to develop a smart ambient bright light (SABL) intervention to provide auto-controlled, consistent indoor lighting that incorporates natural daylight. This SABL includes tunable LED lights, photosensors, and controllers. The SABL system has a pre-programmed 24-hour control schedule for illuminance settings to mimic the natural bright-dark cycle. It will automatically adjust the lights to accommodate the daylight effect to minimize staff burden and maximize the LI effect. The SABL will be installed in participants' bedrooms and designated areas in the dining rooms and activity rooms for four weeks. Each participant will wear a personal light monitor to measure the lighting dosage each participant receives. This study will address three aims: 1) pilot test the effect of SABL on reducing agitation in persons with ADRD, 2) evaluate the fidelity of the SABL delivery, and 3) evaluate the feasibility of implementing the SABL. The study will be conducted in two NHs in Pennsylvania. For aims 1 and 2, the investigators will use a crossover, cluster randomized control trial (RCT) and will enroll residents with ADRD and agitation. For aim 3, the investigators will use a mixed methods design and will interview NH stakeholders to evaluate the acceptability, feasibility, and appropriateness of the intervention. This is the first study that incorporates daylight in ambient light interventions and the first study that addresses the measurement, feasibility, and fidelity of lighting interventions. Findings will establish evidence-based implementation strategies and the best design for SABL to reduce agitation for persons with ADRD in NHs.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 51 (actual)
- First submitted
- 28 Mar 2023
- Start date
- 24 Apr 2023
- Primary completion date
- 30 Oct 2023
- Lead sponsor
- Penn State University
- Diseases
- Alzheimer disease
- NCT number
- NCT05825404
What you commit to
- Study type: Interventional
- Participants enrolled: 51
- From 24 Apr 2023 to the primary completion date, 30 Oct 2023
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Major mental illness
- Severe vision impairment
- Severe acute or terminal illness
- Staff participants:
Other
- Major sleep problems
Who the study is looking for
- Age≥55
- English speaking
- Nursing home residency≥3 months
- Clinical Diagnosis of Alzheimer's Disease and related dementia
- Presence of agitation over the past week
- Age≥18
- English speaking
- Employed as a certified nurse assistant (CNA), activity staff, nurse, director of nursing (DON), director of maintenance, administer or other leadership position for at least 3 months. The CNA, activity staff, and nurse must have direct care interactions with the resident participant(s).
Criteria the registry did not label
- Resident participants
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Valley View Retirement Community Coordinator of this site? Confirm its status | Belleville | United States | Unknown status |
| Christ the King Manor Coordinator of this site? Confirm its status | DuBois | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.